Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma : A MASK-air study. / Sousa-Pinto, B.; Louis, R.; Anto, J. M.; Amaral, R.; Sá-Sousa, A.; Czarlewski, W.; Brussino, L.; Canonica, G. W.; Chaves Loureiro, C.; Cruz, A. A.; Gemicioglu, B.; Haahtela, T.; Kupczyk, M.; Kvedariene, V.; Larenas-Linnemann, D. E.; Okamoto, Y.; Ollert, M.; Pfaar, O.; Pham-Thi, N.; Puggioni, F.; Regateiro, F. S.; Romantowski, J.; Sastre, J.; Scichilone, N.; Taborda-Barata, L.; Ventura, M. T.; Agache, I.; Bedbrook, A.; Becker, S.; Bergmann, K. C.; Bosnic-Anticevich, S.; Bonini, M.; Boulet, L. P.; Brusselle, G.; Buhl, R.; Cecchi, L.; Charpin, D.; de Blay, F.; Del Giacco, S.; Ivancevich, J. C.; Jutel, M.; Klimek, L.; Kraxner, H.; Kuna, P.; Laune, D.; Makela, M.; Morais-Almeida, M.; Nadif, R.; Niedoszytko, M.; Papadopoulos, N. G.; Papi, A.; Patella, V.; Pétré, B.; Rivero Yeverino, D.; Robalo Cordeiro, C.; Roche, N.; Rouadi, P. W.; Samolinski, B.; Savouré, M.; Shamji, M. H.; Sheikh, A.; Suppli Ulrik, C.; Usmani, O. S.; Valiulis, A.; Yorgancioglu, A.; Zuberbier, T.; Fonseca, J. A.; Costa, E. M.; Bousquet, J.
I: Pulmonology, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma
T2 - A MASK-air study
AU - Sousa-Pinto, B.
AU - Louis, R.
AU - Anto, J. M.
AU - Amaral, R.
AU - Sá-Sousa, A.
AU - Czarlewski, W.
AU - Brussino, L.
AU - Canonica, G. W.
AU - Chaves Loureiro, C.
AU - Cruz, A. A.
AU - Gemicioglu, B.
AU - Haahtela, T.
AU - Kupczyk, M.
AU - Kvedariene, V.
AU - Larenas-Linnemann, D. E.
AU - Okamoto, Y.
AU - Ollert, M.
AU - Pfaar, O.
AU - Pham-Thi, N.
AU - Puggioni, F.
AU - Regateiro, F. S.
AU - Romantowski, J.
AU - Sastre, J.
AU - Scichilone, N.
AU - Taborda-Barata, L.
AU - Ventura, M. T.
AU - Agache, I.
AU - Bedbrook, A.
AU - Becker, S.
AU - Bergmann, K. C.
AU - Bosnic-Anticevich, S.
AU - Bonini, M.
AU - Boulet, L. P.
AU - Brusselle, G.
AU - Buhl, R.
AU - Cecchi, L.
AU - Charpin, D.
AU - de Blay, F.
AU - Del Giacco, S.
AU - Ivancevich, J. C.
AU - Jutel, M.
AU - Klimek, L.
AU - Kraxner, H.
AU - Kuna, P.
AU - Laune, D.
AU - Makela, M.
AU - Morais-Almeida, M.
AU - Nadif, R.
AU - Niedoszytko, M.
AU - Papadopoulos, N. G.
AU - Papi, A.
AU - Patella, V.
AU - Pétré, B.
AU - Rivero Yeverino, D.
AU - Robalo Cordeiro, C.
AU - Roche, N.
AU - Rouadi, P. W.
AU - Samolinski, B.
AU - Savouré, M.
AU - Shamji, M. H.
AU - Sheikh, A.
AU - Suppli Ulrik, C.
AU - Usmani, O. S.
AU - Valiulis, A.
AU - Yorgancioglu, A.
AU - Zuberbier, T.
AU - Fonseca, J. A.
AU - Costa, E. M.
AU - Bousquet, J.
N1 - Publisher Copyright: © 2023 Sociedade Portuguesa de Pneumologia
PY - 2024
Y1 - 2024
N2 - Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
AB - Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
KW - Adherence
KW - Asthma
KW - Formoterol
KW - Inhaled corticosteroids
KW - Long-acting-β2 agonist
U2 - 10.1016/j.pulmoe.2023.07.004
DO - 10.1016/j.pulmoe.2023.07.004
M3 - Journal article
C2 - 37543524
AN - SCOPUS:85166957975
JO - Pulmonology
JF - Pulmonology
SN - 2531-0429
ER -
ID: 387030582